Technology ID
TAB-3383

Floxed Targeted Mouse Strain for Use in Conditional Deletion of the Irf8 Gene

E-Numbers
E-062-2012-0
Lead Inventor
Morse, Herbert (NIAID)
Applications
Research Materials
Lead IC
NIAID
ICs
NIAID
IRF8, a member of interferon regulatory factor (IRF) family of transcription factors is a novel intrinsic transcriptional inhibitor of TH17-cell differentiation. TH17-cells are believed to be involved in the pathogenesis of various autoimmune/inflammatory diseases. These materials could be used to help define patterns of gene expression important for the development and function of cells including possible contributions to understanding: normal immune responses, inflammatory conditions, autoimmunity and anti-viral responses.
Commercial Applications
  • Target identification in B and T cell deficiency, macrophage defects and hematopoiesis
  • A tool for investigating IRF8 mediated issues associated with inflammation and autoimmunity
  • Investigative tool for development of potential therapeutics for lymphoma and Human Chronic Myeloid Leukemia
Competitive Advantages
  • Mice with established germ line transmission for use in conditional deletion of the IRF8 gene in any cellt type

Request More Info

Licensing Contact:
Taylor-Mulneix, Dawn
dawn.taylor-mulneix@nih.gov

Publications

Collaborations

  • Collaboration

Collaboration Description

  • The Technology Transfer and Intellectual Property Office (TTIPO) is seeking parties interested in collaborative research to further co-develop this technology by identifying pharmacological compounds inhibiting CD62L shedding by using high throughput compound screening. For collaboration opportunities, please contact Chris Kornak at chris.kornak@nih.govor 1-240-627-3705.
Date Published